申请人:ASCENTAGE PHARMA (SUZHOU) CO., LTD.
公开号:US11312724B2
公开(公告)日:2022-04-26
The present disclosure provides compounds represented by Formula I:
wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and
are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
本公开提供了由式 I 表示的化合物:
其中 R3、A、A1、A2、A3、E、E1、E2、L、Q、Z 和
及其药学上可接受的盐和溶液。式 I 的化合物是 KRAS 抑制剂,因此可用于治疗癌症和其他疾病。